Top Markets
#1 Status Status +19.39%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.43%
#3 GoPlus Security GoPlus Security +12.56%
#4 Fake World Assets Fake World Assets +10.48%
#5 DMT-NAT DMT-NAT +9.49%
#6 Ontology Gas Ontology Gas +9.19%
#7 Provenance Blockchain Provenance Blockchain +6.74%
#8 o1.exchange o1.exchange +6.72%
#9 Janction Janction +6.56%
#10 B3 (Base) B3 (Base) +5.41%
Coin of the day
Status Status
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Peringkat dalam Saham #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Harga Saham
$0.1502
Terakhir disinkronkan: 2024-11-04
Kapitalisasi Pasar
$6.43M
Perubahan (1 hari)
-5.45%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Renalytix Plc (RNLX)

Kategori

Healthcare
Rasio P/S untuk Renalytix Plc (RNLX)
Rasio P/S per August 2026 TTM: 9.85
Menurut laporan keuangan dan harga saham terbaru dari Renalytix Plc, rasio P/S saat ini (TTM) adalah 9.85. Pada akhir 2023, rasio P/S perusahaan adalah 35.27.
Riwayat rasio P/S untuk Renalytix Plc dari 2018 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 9.85 66.11%
2024 5.93 -83.19%
2023 35.27 25.79%
2022 28.04 -96.18%
2021 733.39 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/S Perbedaan Rasio P/S Negara
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
1.64 -83.31%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
77.67 688.51%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
0.84 -91.45%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
6.37 -35.29%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
- -
US